Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
- 1k Downloads
The Oncotype DX® Recurrence Score® (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer. Adjuvant! was developed using SEER registry data and results from the Early Breast Cancer Clinical Trialists’ overview analyses to estimate outcome and benefit from adjuvant hormonal therapy and chemotherapy. In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer. RS and Adjuvant! results were available from 668 tamoxifen-treated NSABP B-14 patients, 227 tamoxifen-treated NSABP B-20 patients, and 424 chemotherapy plus tamoxifen-treated B-20 patients. Adjuvant! results were also available from 1952 B-20 patients. The primary endpoint was distant recurrence-free interval (DRFI). Cox proportional hazards models were used to compare the prognostic and predictive utility of RS and Adjuvant!. Both RS (P < 0.001) and Adjuvant! (P = 0.002) provided strong independent prognostic information in tamoxifen-treated patients. Combining RS and individual clinicopathologic characteristics provided greater prognostic discrimination than combining RS and the composite Adjuvant!. In the B-20 cohort with RS results (n = 651), RS was significantly predictive of chemotherapy benefit (interaction P = 0.031 for DRFI, P = 0.011 for overall survival [OS], P = 0.082 for disease-free survival [DFS]), but Adjuvant! was not (interaction P = 0.99, P = 0.311, and P = 0.357, respectively). However, in the larger B-20 sub-cohort (n = 1952), Adjuvant! was significantly predictive of chemotherapy benefit for OS (interaction P = 0.009) but not for DRFI (P = 0.219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit.
KeywordsBreast cancer Oncotype DX Recurrence Score Adjuvant! Node-negative ER-positive
This study is supported in part by Public Health Service Grants U10CA-12027, U10CA-69974, U10CA-37377, U10CA-69651, and U24-CA-114732 from the National Cancer Institute, Department of Health and Human Services. The funding source did not affect the study design, data collection, analysis, interpretation, writing, or submission of this work. We would like to thank Dr. Drew Watson, Genomic Health, for valuable discussions during this study.
Conflicts of interest
Even though the NSABP Statistical Center has received research funding from Genomic Health, this study was not supported by Genomic Health. SS is a full-time employee and a stockholder in Genomic Health. GT, SJA, and JPC declare no potential conflicts of interest. EPM has been a consultant and on the speaker’s bureau of Genomic Health. There are no other potential conflicts of interest reported.
- 6.Dowsett M, Cuzick J, Wales C et al (2009) Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Cancer 69:75 abstr 53Google Scholar
- 9.Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65PubMedCrossRefGoogle Scholar
- 11.NCCN Clinical Practice Guidelines in OncologyTM Breast Cancer, (Version 2.2008). http://www.nccn.org. Accessed 18 Sept 2008
- 13.Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 17 Regs Limited Use + Katrina Impacted Louisiana Cases. Nov Released April 2008, based on the November 2007 submission. Surveillance Research Program, National Cancer Institute SEER* Software. [version 6.4.4]. www.seer.cancer.gov/seerstat. Accessed 29 Jan 2010
- 17.Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829–1834PubMedCrossRefGoogle Scholar